Back to Report Store Home

Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS

  • Published: May-2011
  • Report Code: GBIHC087MR
  • Report Format: pdf

Description

List of Tables

Table 1: Risk Evaluation and Mitigation Strategies, List of FDA Approved REMS, 2008

Table 2: Risk Evaluation and Mitigation Strategies, List of FDA Approved REMS, 2009

Table 3: Risk Evaluation and Mitigation Strategies, List of FDA Approved REMS, 2010

Table 4: Risk Evaluation and Mitigation Strategies, Deemed REMS, 2010

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards